AstraZeneca Given “Market Perform” Rating at Leerink Swann (AZN)
AstraZeneca (NYSE:AZN)‘s stock had its “market perform” rating reiterated by Leerink Swann in a research note issued on Monday, AnalystRatingsNetwork.com reports.
AstraZeneca (NYSE:AZN) traded up 0.66% during mid-day trading on Monday, hitting $52.11. The stock had a trading volume of 412,315 shares. AstraZeneca has a 1-year low of $44.17 and a 1-year high of $53.45. The stock’s 50-day moving average is $50. and its 200-day moving average is $50.28. The company has a market cap of $65.242 billion and a P/E ratio of 13.21.
AstraZeneca (NYSE:AZN) last released its earnings data on Thursday, August 1st. The company reported $1.20 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.16 by $0.04. The company had revenue of $6.23 billion for the quarter, compared to the consensus estimate of $6.24 billion. During the same quarter last year, the company posted $1.53 earnings per share. AstraZeneca’s revenue was down 6.4% compared to the same quarter last year. Analysts expect that AstraZeneca will post $5.19 EPS for the current fiscal year.
AZN has been the subject of a number of other recent research reports. Analysts at Nordea Equity Research upgraded shares of AstraZeneca (NYSE:AZN) from a “sell” rating to a “buy” rating in a research note to investors on Monday, September 16th. Separately, analysts at Danske downgraded shares of AstraZeneca (NYSE:AZN) from a “hold” rating to a “sell” rating in a research note to investors on Tuesday, September 3rd. Finally, analysts at Morgan Stanley downgraded shares of AstraZeneca (NYSE:AZN) from an “equal weight” rating to an “underweight” rating in a research note to investors on Thursday, August 15th. Six analysts have rated the stock with a sell rating, ten have given a hold rating and one has assigned a buy rating to the company’s stock. AstraZeneca currently has an average rating of “Hold” and an average price target of $51.33.
AstraZeneca PLC (NYSE:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.